LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
Latest BioSpace coverage of LEO adds to dermatology portfolio with $435M deal for late-stage rare disease dr
Leo Pharma
Leo Pharma is a privately held Danish dermatology company developing treatments for skin diseases including psoriasis, eczema, and rare conditions like generalized pustular psoriasis (GPP).
Company Info
Recent News
Leo Pharma gears up for GPP awareness day
Abbott is again tapping into the competitive spirit of Big Ten universities to drive blood donations,
Leo Pharma readies rare disease education push for 2nd annual GPP awareness day
The company and the National Psoriasis Foundation will celebrate the second annual Generalized Pustular Psoriasis Awareness day on August 13.